Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999

TY - JOUR

T1 - Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999

AU - Mocroft, A

AU - Horban, A

AU - Clotet, B

AU - d'Arminio Monforte, A

AU - Bogner, J R

AU - Aldins, P

AU - Staub, T

AU - Antunes, F

AU - Katlama, C

AU - Lundgren, J D

AU - Eurosida Study Group

N1 - Keywords: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Europe; Female; HIV Infections; Humans; Male; Risk; Treatment Failure; Viral Load

PY - 2008

Y1 - 2008

N2 - Regional differences across Europe in triple class failure (TCF; the failure of each of the three separate main classes of antiretrovirals (ARVs) with a viral load >1000 HIV-1 RNA copies/mL for >4 months) have not been described. A total of 1956 patients started combination ARV therapy after 1 January 1999, of whom 123 patients developed TCF [6.3%; incidence 16.7 per 1000 person-years of follow-up; 95% confidence interval (CI) 13.7-19.6]. After adjustment, patients from Eastern Europe had a significantly increased incidence of TCF compared with patients from Southern Europe/Argentina (3.05; 95% CI 1.36-6.82; P=0.0067) while patients taking either a boosted protease inhibitor regimen (0.33; 95% CI 0.15-0.74; P=0.0072) or a nonnucleotide reverse transcriptase inhibitor (NNRTI)-based regimen (0.59; 95% CI 0.37-0.94; P=0.026) had a reduced incidence of TCF.

AB - Regional differences across Europe in triple class failure (TCF; the failure of each of the three separate main classes of antiretrovirals (ARVs) with a viral load >1000 HIV-1 RNA copies/mL for >4 months) have not been described. A total of 1956 patients started combination ARV therapy after 1 January 1999, of whom 123 patients developed TCF [6.3%; incidence 16.7 per 1000 person-years of follow-up; 95% confidence interval (CI) 13.7-19.6]. After adjustment, patients from Eastern Europe had a significantly increased incidence of TCF compared with patients from Southern Europe/Argentina (3.05; 95% CI 1.36-6.82; P=0.0067) while patients taking either a boosted protease inhibitor regimen (0.33; 95% CI 0.15-0.74; P=0.0072) or a nonnucleotide reverse transcriptase inhibitor (NNRTI)-based regimen (0.59; 95% CI 0.37-0.94; P=0.026) had a reduced incidence of TCF.

U2 - 10.1111/j.1468-1293.2008.00519.x

DO - 10.1111/j.1468-1293.2008.00519.x

M3 - Journal article

C2 - 18199171

SN - 1464-2662

VL - 9

SP - 41

EP - 46

JO - HIV Medicine

JF - HIV Medicine

IS - 1

ER -